Tag: TCT 2021

“Promising” early data shared on alternatives to paclitaxel DCBs at TCT 2021

Early data presented at the Transcatheter Cardiovascular Therapeutics annual meeting (TCT 2021; ...

Lessons from SURTAVI

Transcatheter aortic valve implantation (TAVI) pioneer and principal investigator of the SURTAVI tri...

TCT 2021: BIOSOLVE-IV data offer reassurance over rates of scaffold thrombosis from Magmaris bioresorbable scaffold

Data from the BIOSOLVE-IV trial, presented at the Transcatheter Cardiovascular Therapeutics annu...

TCT 2021: Six-month TRISCEND results “encouraging” for Evoque tricuspid valve

Six-month results from the TRISCEND study of the Evoque (Edwards Lifesciences) transcatheter tri...

TCT 2021: Early data presented for Intrepid TMVR using transfemoral delivery system

Early data for the self-expanding Intrepid (Medtronic) transcatheter mitral valve replacement (T...

TCT 2021: SWISS-APERO trial finds lower rate of peri-device leak in Amulet compared to Watchman FLX LAAC device

Findings of the SWISS-APERO trial, presented at the Transcatheter Cardiovascular Therapeutics an...

TCT 2021: Endoscopy study could have implications for post-PCI antiplatelet regimens

Patients receiving antiplatelet therapy following percutaneous coronary intervention (PCI) devel...

TCT 2021: Studies show improved outcomes for high-risk PCI patients using Impella

The final results of the PROTECT III and Restore EF prospective studies demonstrate improved out...

TCT 2021: LAAC remains non-inferior to NOAC for cardiovascular events at long-term follow-up

Left atrial appendage occlusion (LAAC) remains non-inferior to non vitamin-K-antagonists (NOACs)...

TCT 2021: Five-year SURTAVI data show comparable performance for TAVI and SAVR on mortality, stroke

Five-year clinical and echocardiographic outcome data from the SURTAVI randomised trial comparin...

TCT 2021: TAVI in low-risk patients is cost effective, PARTNER 3 finds

An economic analysis of data from the PARTNER 3 randomised trial, comparing transcatheter aortic...

TCT 2021: CHEETAH study demonstrates safety of continuous aspiration to remove blood clots in the heart

Penumbra has announced that the CHEETAH clinical study of its Indigo system CAT RX catheter succ...

TCT 2021: “Sustained benefit” in patients undergoing IVL prior to coronary stenting

One-year outcomes from the Disrupt CAD III clinical study of Shockwave intravascular lithotripsy (IV...

TCT 2021: Patients with diabetes undergoing PCI have less target lesion failure with amphilimus-eluting stents

Results from SUGAR, a randomised controlled, multicentre trial conducted exclusively in patients wit...

TCT 2021: Six-month RADIANCE-HTN TRIO results “open a window” for renal denervation

Six-month outcomes from the randomised RADIANCE-HTN TRIO trial, comparing endovascular ultrasoun...

TCT 2021: QFR-guided lesion selection improves PCI outcomes in FAVOR III trial

Lesion selection for percutaneous coronary intervention (PCI) using the non-invasively assessed phys...

TCT 2021: CABG “remains the treatment of choice” for complex, three-vessel coronary artery disease

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) did not meet no...

TCT 2021: Medtronic unveils data on hypertension treatment preferences, launches SPYRAL AFFIRM study

Medtronic has announced findings from a new study of patient preferences for the treatment of hypert...

Procyrion’s Aortix percutaneous mechanical circulatory support device features at TCT 2021

Procyrion has announced the presentation of studies at the Transcatheter Cardiovascular Therapeutics...

CRF waives cost for digital access to TCT 2021

The Cardiovascular Research Foundation (CRF) has announced that the digital component of the Transca...